bromocriptine has been researched along with Diabetes Mellitus, Adult-Onset in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.88) | 18.2507 |
| 2000's | 4 (7.84) | 29.6817 |
| 2010's | 34 (66.67) | 24.3611 |
| 2020's | 10 (19.61) | 2.80 |
| Authors | Studies |
|---|---|
| Akhtar, MF; Akter, R; Al-Harrasi, A; Berrada, M; Bhatia, S; Damiri, F; Ferdous Mitu, J; Kabir, MT; Rahman, MH; Rahman, MS; Saleem, A | 1 |
| Abbas, M; Mahmood, Q; Mahmood, Z; Malik, A; Mehmood, MH; Naz, F; Rasool, G; Riaz, M | 1 |
| Adams, J; Agyin, C; Alatrach, M; Cersosimo, E; Chamarthi, B; Chilton, R; Cincotta, AH; Cominos, N; DeFronzo, RA; Ezrokhi, M; Triplitt, C | 1 |
| Cincotta, AH | 1 |
| Aslanoglou, D; Benner, V; Farino, ZJ; Freyberg, Z; Lopez-Valencia, M; McCarthy, MJ; Osborn, O; Wei, H; Zapata, RC | 1 |
| Araki, E; Hanatani, S; Igata, M; Ishii, N; Kawashima, J; Motoshima, H; Sakaguchi, M; Yagi, Y; Yoshinaga, K | 1 |
| Bloomgarden, Z; Cao, M | 1 |
| Davis, S; Siamashvili, M | 1 |
| Bloomgarden, Z | 1 |
| Barra, C; Conde, SV; Costa, A; Gasparini, P; Marques, D; Matafome, P; Melo, BF; Rodrigues, T; Rosendo-Silva, D; Sacramento, JF; Seiça, R; Tavares, G | 1 |
| Chamarthi, B; Cincotta, AH | 1 |
| Kim, J; Tillman, F | 1 |
| Michael Besser, G; Pfeiffer, RF; Thorner, MO | 1 |
| Goldman, JD | 1 |
| Bartolini, P; Buonfiglio, DC; de Alencar, A; Donato, J; Furigo, IC; Oliveira, JE; Pedroso, JA; Prada, PO; Quaresma, PGF; Ramos-Lobo, AM; Soares, CRJ; Suzuki, MF; Teixeira, PDS; Zampieri, TT | 1 |
| Ashida, K; Kawano, S; Nakamura, Y; Nakayama, H; Nomura, M; Ohki, T; Oshige, T; Sasaki, Y; Tajiri, Y; Tokubuchi, I; Tsuruta, M; Yamada, K | 1 |
| Grunberger, G | 1 |
| Hilaire, ML; Weiland, CM | 1 |
| Alvarez-Aguilar, C; Avila-Diaz, M; Belio-Caro, F; Ceballos-Reyes, G; García-López, E; Herrera-Abarca, JE; Lindholm, B; Mejía-Rodríguez, O; Paniagua, R; Prado-Uribe, C; Salinas-González, A; Vega-Gomez, H | 1 |
| Bretón Lesmes, I; Cózar León, MV; García de Quirós Muñoz, JM; Serrano Aguayo, P | 1 |
| Bondareva, VM; Chistyakova, OV; Derkach, KV; Shpakov, AO | 1 |
| Bondareva, VM; Derkach, KV; Moyseyuk, IV; Shpakov, AO | 1 |
| Blonde, L; Chamarthi, B; Cincotta, AH; Ezrokhi, M; Gaziano, JM; Rutty, D; Scranton, RE; Vinik, A | 1 |
| Chamarthi, B; Raskin, P; Roe, ED | 1 |
| Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W | 1 |
| Chen, S; Gao, L; Hou, J; Jiang, Y; Li, N; Liang, W; Pan, H; Wang, B; Wang, L; Wang, Y; Yang, H; You, L; Zhu, H | 1 |
| Lamos, EM; Levitt, DL; Munir, KM | 1 |
| Becu-Villalobos, D; Brie, B; Garcia Tornadu, I; Lopez Vicchi, F; Luque, GM; Nogueira, JP | 1 |
| Schwartz, SS; Zangeneh, F | 1 |
| Chamarthi, B; Cincotta, AH; Ezrokhi, M; Rutty, D | 1 |
| Belavic, JM | 1 |
| Cincotta, A; Scranton, R | 1 |
| Cincotta, AH; Ezrokhi, M; Gaziano, JM; Ma, ZJ; O'Connor, CM; Rutty, D; Scranton, RE | 1 |
| Bailey, CJ; Barnett, AH; Holt, RI | 1 |
| Kerr, JL; Petkewicz, KA; Timpe, EM | 1 |
| Defronzo, RA | 1 |
| Bell, DS | 2 |
| Mikhail, N | 1 |
| Sando, KR; Taylor, J | 1 |
| Agrawal, N; Kalra, B; Kalra, S; Kumar, S | 1 |
| Matsuda, M | 1 |
| Blonde, L; Bohannon, N; Cincotta, AH; Gaziano, JM; Scranton, R; Vinik, A | 1 |
| Amini, M; Aminorroaya, A; Haghighi, S; Janghorbani, M; Ramezani, M | 1 |
| Roush, W | 1 |
| Cincotta, AH; Jetton, TL; Liang, Y; Lubkin, M; Meier, AH | 1 |
| Iwamoto, Y; Kawahara, R; Wasada, T | 1 |
| Reaven, GM | 1 |
| Cincotta, AH; DeFronzo, RA; Iozzo, P; Kumar, V; Lancaster, JL; Mahankali, A; Matsuda, M; Miyazaki, Y; Ohashi, S; Pijl, H; Pipek, R | 1 |
| Cincotta, AH; Lovell, WC; Meier, AH | 1 |
20 review(s) available for bromocriptine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus.
Topics: Bromocriptine; Cabergoline; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans; Hyperprolactinemia; Parkinson Disease; Restless Legs Syndrome | 2022 |
Bromocriptine therapy: Review of mechanism of action, safety and tolerability.
Topics: Acromegaly; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin | 2022 |
Brain Dopamine-Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects.
Topics: Animals; Brain; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dopamine; Dopamine Agonists; Insulin; Insulin Resistance; Insulin, Regular, Human; Metabolic Syndrome | 2023 |
Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans; Hypoglycemic Agents; Receptors, Dopamine D2; Risk Reduction Behavior | 2021 |
Select medications that unexpectedly lower HbA1c levels.
Topics: Blood Glucose; Bromocriptine; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents | 2018 |
ANNIVERSARY REVIEW: 50 years since the discovery of bromocriptine.
Topics: Acromegaly; Animals; Anniversaries and Special Events; Antiparkinson Agents; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Drug Discovery; Drug Therapy, Combination; Ergotism; History, 20th Century; Hormone Antagonists; Humans; Hyperprolactinemia; Hypoglycemic Agents; Parkinson Disease; Pituitary Neoplasms | 2018 |
Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.
Topics: Bromocriptine; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Islet Amyloid Polypeptide | 2013 |
Bromocriptine mesylate (Cycloset) for type 2 diabetes mellitus.
Topics: Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans; Hypoglycemic Agents; Treatment Outcome | 2013 |
[Endocrinologic diseases management during breastfeeding].
Topics: Breast Feeding; Bromocriptine; Contraindications; Diabetes Mellitus, Type 2; Diet, Diabetic; Dopamine Agonists; Endocrine System Diseases; Estrogens; Female; Humans; Hyperprolactinemia; Hypoglycemic Agents; Hypopituitarism; Infant; Infant, Newborn; Insulin; Lactation; Milk, Human; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy in Diabetics; Prolactin; Prolactinoma; Puerperal Disorders; Thyroid Diseases | 2015 |
Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Bromocriptine; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Treatment Outcome | 2015 |
A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
Topics: Animals; Biomarkers; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dopamine Agonists; Ergolines; Humans; Hypoglycemic Agents; Risk Factors; Treatment Outcome | 2016 |
Dopaminergic drugs in type 2 diabetes and glucose homeostasis.
Topics: Acromegaly; Animals; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agents; Glucose; Homeostasis; Humans; Parkinson Disease; Polymorphism, Genetic; Prolactinoma; Receptors, Dopamine D2 | 2016 |
Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Bromocriptine; Circadian Clocks; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dopamine Agonists; Evidence-Based Medicine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Dopamine D2; Suprachiasmatic Nucleus | 2016 |
Bromocriptine: old drug, new formulation and new indication.
Topics: Bromocriptine; Chemistry, Pharmaceutical; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dopamine Agonists; Glycated Hemoglobin; Humans; Treatment Outcome; United States | 2010 |
Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus.
Topics: Aged; Animals; Blood Glucose; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Drug Interactions; Glycated Hemoglobin; Humans; Receptors, Dopamine D2 | 2010 |
Bromocriptine (Cycloset) for type 2 diabetes.
Topics: Animals; Bromocriptine; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans; Nausea; Randomized Controlled Trials as Topic | 2010 |
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
Topics: Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans | 2011 |
Why does quick-release bromocriptine decrease cardiac events?
Topics: Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Oxidative Stress; Postprandial Period | 2011 |
Dopamine: the forgotten felon in type 2 diabetes.
Topics: Animals; Body Weight; Bromocriptine; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dopamine Agonists; Dopaminergic Neurons; Drug Interactions; Energy Metabolism; Glucose; Humans; Patents as Topic | 2011 |
Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR.
Topics: Blood Glucose; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dopamine Agonists; Humans; Hyperglycemia; Risk Assessment | 2012 |
11 trial(s) available for bromocriptine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Treatment Outcome | 2017 |
Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease.
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Bromocriptine; Demography; Diabetes Mellitus, Type 2; Echocardiography; Female; Heart; Heart Ventricles; Hormone Antagonists; Humans; Kidney; Male; Middle Aged; Organ Size; Placebos; Renal Insufficiency, Chronic | 2013 |
Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
Topics: Aged; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Disease Progression; Dopamine Agonists; Double-Blind Method; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome | 2015 |
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Dopamine Agonists; Exercise; Female; Fibrinogen; Homocysteine; Humans; Hypercholesterolemia; Hyperprolactinemia; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Middle Aged; Premenopause; Risk Factors; Uric Acid | 2015 |
Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
Topics: Aged; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Risk Factors | 2016 |
Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.
Topics: Aged; Bromocriptine; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dopamine Agonists; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Placebos; Risk Factors; Risk Reduction Behavior; Treatment Outcome | 2010 |
Quick-release bromocriptine for treatment of type 2 diabetes.
Topics: Blood Glucose; Bromocriptine; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents; Placebos; Postprandial Period | 2011 |
Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.
Topics: Aged; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dopamine Agonists; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Receptors, Dopamine D2; Risk Factors; Treatment Outcome | 2012 |
Does bromocriptine improve glycemic control of obese type-2 diabetics?
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Double-Blind Method; Drug Synergism; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Placebos | 2004 |
Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Blood Glucose; Body Mass Index; Body Weight; Bromocriptine; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Female; Glucose Tolerance Test; Glycated Hemoglobin; Hormone Antagonists; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Placebos; Time Factors; Viscera | 2000 |
Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics.
Topics: Body Composition; Bromocriptine; Diabetes Mellitus, Type 2; Fats; Female; Humans; Hyperglycemia; Male; Menopause; Obesity; Skinfold Thickness | 1992 |
20 other study(ies) available for bromocriptine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects.
Topics: Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycogen Synthase Kinase 3 beta; Humans; Interleukin-18; L-Selectin; Leukocytes, Mononuclear; NF-E2-Related Factor 2; NIMA-Interacting Peptidylprolyl Isomerase; NLR Family, Pyrin Domain-Containing 3 Protein; Normetanephrine; Oxidative Stress; Phenotype; Prolactin; RNA, Messenger; Superoxide Dismutase-1; Sympatholytics; Thiobarbituric Acid Reactive Substances; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2022 |
Dopamine D
Topics: Animals; Blood Glucose; Bromocriptine; Circadian Rhythm; Diabetes Mellitus, Type 2; Dopamine; Dopamine Agonists; Female; Glucose; Insulin; Insulin-Secreting Cells; Levodopa; Mice; Mice, Inbred C57BL; Obesity; Receptors, Dopamine D2; Sulpiride; Weight Gain | 2020 |
Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.
Topics: Blood Glucose; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Female; Humans; Middle Aged; Prolactinoma | 2021 |
New insights into the older hypoglycemic agents in type 2 diabetes therapy.
Topics: Acarbose; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2020 |
Various and sundry recent publications.
Topics: Bromocriptine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Heart Rate; Humans; Insulin Resistance; Obesity | 2021 |
Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes.
Topics: Adult; Aged; Animals; Bariatric Surgery; Bromocriptine; Cohort Studies; Diabetes Mellitus, Type 2; Disease Models, Animal; Dopamine; Dopamine Agonists; Female; Humans; Insulin Resistance; Intra-Abdominal Fat; Lipid Metabolism; Male; Metabolic Networks and Pathways; Metabolome; Metabolomics; Middle Aged; Obesity; Rats; Receptors, Dopamine D2 | 2021 |
Antihyperglycemic medications for cardiovascular disease risk reduction.
Topics: Benzhydryl Compounds; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Risk Reduction Behavior; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2018 |
Suppression of Prolactin Secretion Partially Explains the Antidiabetic Effect of Bromocriptine in ob/ob Mice.
Topics: Animals; Blood Glucose; Bromocriptine; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Liver; Male; Mice; Mice, Obese; Muscle, Skeletal; Prolactin | 2019 |
Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes.
Topics: Amenorrhea; Bromocriptine; Diabetes Mellitus, Type 2; Female; Galactorrhea; Hormone Antagonists; Humans; Magnetic Resonance Imaging; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Young Adult | 2019 |
The influence of bromocryptine treatment on activity of the adenylyl cyclase system in the brain of rats with type 2 diabetes mellitus induced by high-fat diet.
Topics: Adenylyl Cyclases; Animals; Blood Glucose; Body Weight; Brain; Bromocriptine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dopamine; Hypoglycemic Agents; Male; Norepinephrine; Rats, Wistar; Receptors, Dopamine D2; Relaxin; Serotonin; Somatostatin | 2014 |
[The influence of two-month treatment with bromocryptine on activity of the adenylyl cyclase signaling system in the myocardium and testes of rats with type 2 diabetes mellitus].
Topics: Adenylyl Cyclases; Administration, Oral; Animals; Blood Glucose; Bromocriptine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dioxoles; Dopamine Agonists; Drug Administration Schedule; Ethanolamines; Guanylyl Imidodiphosphate; Humans; Insulin Resistance; Isoproterenol; Male; Myocardium; Norepinephrine; Rats; Rats, Wistar; Relaxin; Signal Transduction; Streptozocin; Testis; Triglycerides | 2014 |
Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.
Topics: Adult; Aged; Blood Glucose; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pilot Projects; Treatment Outcome | 2015 |
A new treatment option for type 2 diabetes.
Topics: Bromocriptine; Diabetes Mellitus, Type 2; Hormone Antagonists; Humans; Hyperglycemia; Nurse Practitioners | 2010 |
Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.
Topics: Blood Glucose; Bromocriptine; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans; Hypoglycemia; Hypoglycemic Agents; Postprandial Period; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Weight Gain | 2010 |
Bromocriptine: its place in type 2 diabetes Tx.
Topics: Blood Glucose; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Glycated Hemoglobin; Humans; Hypoglycemic Agents | 2011 |
[Bromocriptine].
Topics: Animals; Bromocriptine; Diabetes Mellitus, Type 2; Humans | 2012 |
Can "resetting" hormonal rhythms treat illness?
Topics: Animals; Bromocriptine; Circadian Rhythm; Clinical Trials, Phase III as Topic; Darkness; Diabetes Mellitus, Type 2; Humans; Light; Melatonin; Obesity; Prolactin | 1995 |
Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse.
Topics: Animals; Blood Glucose; Bromocriptine; Corticosterone; Diabetes Mellitus, Type 2; Disease Models, Animal; Dopamine Agonists; Fluorescent Antibody Technique; Immunohistochemistry; Insulin; Islets of Langerhans; Lipids; Mice; Mice, Obese; Pancreas | 1998 |
Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients.
Topics: Abdomen; Adipose Tissue; Blood Glucose; Bromocriptine; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dopamine Agonists; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Male; Middle Aged; Obesity; Prolactin; Skin | 2000 |
Are the results really different?
Topics: Blood Glucose; Bromocriptine; Cholesterol, HDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dopamine Agonists; Female; Humans; Insulin Resistance; Obesity | 2000 |